DELirium, Incidence, preVEntion and pRogression During Acute Intensive Neurological -Neurosurgical Rehabilitation (DeliVeriNN)

July 17, 2025 updated by: Ralf Degenhardt, PhD, Heart Centre Rotenburg

DELirium, Incidence, preVEntion and pRogression During Acute Intensive Neurological -Neurosurgical Rehabilitation (Delirinzidenz Und Verlauf während Des Aufenthaltes in Der Neurologisch- Neurochirurgischen Frührehablilitation Der Phase B (NNFR))

In this longitudinal cohort study the incidence of delirium is assessed for all patients being admitted to the acute intensive neurological-neurosurgical rehabilitation over 3 years. Delirium assessment will be performed daily from admission to discharge. Patients will be divided into 3 groups, according to the presentation of delirium on admission, during the course or not any during the stay in acute rehabilitation and compared regarding the treatment and outcome.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

210

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Germany
      • Rotenburg An Der Fulda, Germany, 36199
        • Herz-Kreislauf-Zentrum Klinikum Hersfeld Rotenburg GmbH, Klinik für Neurologie und Neurologische Rehabilitation
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients in Neurosurgical rehabilitation

Description

Inclusion Criteria:

  • Any patient admitted to acute neurological-seurosurgical rehabilitation

Exclusion Criteria:

  • : patients with level of consciousness of coma or vegetative state

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
incidence of delirium
Time Frame: 3 years
3 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Heart Centre Rotenburg

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

August 15, 2025

Primary Completion (Estimated)

August 15, 2028

Study Completion (Estimated)

February 15, 2029

Study Registration Dates

First Submitted

July 8, 2025

First Submitted That Met QC Criteria

July 16, 2025

First Posted (Actual)

July 17, 2025

Study Record Updates

Last Update Posted (Actual)

July 22, 2025

Last Update Submitted That Met QC Criteria

July 17, 2025

Last Verified

July 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • DeliVeriNN-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neurological Conditions

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe